ENUMERATION AND CHARACTERISATION OF CIRCULATING TUMOR CELLS (CTC) IN PATIENTS WITH SOLID MALIGNANCIES - Circulating Tumor Cells, solid malignancies

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 900 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•- Patients suffering from one of the below mentioned solid malignancies. For patients with metastatic disease, only those who will be treated with first line systemic treatment will be recruited.
•o metastatic breast cancer (number 100-150)
•o localized breast cancer (number 100-150)
•o metastatic colorectal cancer (number 100-150)
•o localized colorectal cancer (number 100-150)
•o metastatic prostate cancer (number 100-150)
•o metastatic other tumor types such as testicular cancer, soft tissue sarcoma, renal cell carcinoma, lung carcinoma (in total maximum number 100-150);- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.;- Before patient randomization, written informed consent must be given and documented to ICH/EU GCP, and national/local regulatory requirements and the local rules followed in the institution

发起方